Axcelead Drug Discovery Partners (DDP) is a Japan-based contract research organization formed in 2017 as a Takeda spin-out, specializing in preclinical drug discovery and development. Their end-to-end platform covers target identification/validation, hit identification, lead generation/optimization, and candidate selection through IND-enabling studies. Axcelead focuses on small molecules, targeted protein degraders (TPDs), RNA-targeted small molecules, oligonucleotides, and peptides across oncology, immunology, and neuroscience therapeutic areas. The company leverages high-throughput screening, omics technologies, bioinformatics, and chemistry capabilities. They are a pure discovery/preclinical CRO and do not manufacture drug products.
preclinical drug discovery, targeted protein degradation, RNA-targeted small molecules, high-throughput screening, omics/bioinformatics, medicinal chemistry
1 site worldwide
No certifications on file yet.
No reviews available yet.
No documents available.